Bill Maughan
Stock Analyst at Clear Street
(0.97)
# 4,104
Out of 5,182 analysts
23
Total ratings
37.5%
Success rate
-17.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Buy | $100 → $130 | $86.20 | +50.81% | 2 | Mar 10, 2026 | |
| OCUL Ocular Therapeutix | Maintains: Buy | $21 → $28 | $8.34 | +235.73% | 1 | Mar 3, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $10 → $18 | $13.91 | +29.40% | 2 | Feb 19, 2026 | |
| CRBU Caribou Biosciences | Initiates: Buy | $13 | $1.86 | +598.92% | 1 | Feb 2, 2026 | |
| CLLS Cellectis | Initiates: Buy | $9 | $3.39 | +165.49% | 1 | Dec 23, 2025 | |
| WVE Wave Life Sciences | Maintains: Buy | $22 → $47 | $7.10 | +561.97% | 2 | Dec 9, 2025 | |
| ANNX Annexon | Initiates: Buy | $17 | $5.99 | +183.81% | 1 | Dec 2, 2025 | |
| KRYS Krystal Biotech | Initiates: Buy | $190 | $263.99 | -28.03% | 1 | Jul 1, 2025 | |
| CRSP CRISPR Therapeutics AG | Downgrades: Hold | $45 | $49.70 | -9.46% | 1 | Jun 27, 2025 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $2.25 | +566.67% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $9 | $1.15 | +682.61% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $63 → $67 | $31.96 | +109.64% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $91 → $106 | $50.11 | +111.53% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $24 | $2.26 | +961.95% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $4.90 | +1,124.49% | 1 | Feb 21, 2024 |
Dianthus Therapeutics
Mar 10, 2026
Maintains: Buy
Price Target: $100 → $130
Current: $86.20
Upside: +50.81%
Ocular Therapeutix
Mar 3, 2026
Maintains: Buy
Price Target: $21 → $28
Current: $8.34
Upside: +235.73%
Korro Bio
Feb 19, 2026
Upgrades: Buy
Price Target: $10 → $18
Current: $13.91
Upside: +29.40%
Caribou Biosciences
Feb 2, 2026
Initiates: Buy
Price Target: $13
Current: $1.86
Upside: +598.92%
Cellectis
Dec 23, 2025
Initiates: Buy
Price Target: $9
Current: $3.39
Upside: +165.49%
Wave Life Sciences
Dec 9, 2025
Maintains: Buy
Price Target: $22 → $47
Current: $7.10
Upside: +561.97%
Annexon
Dec 2, 2025
Initiates: Buy
Price Target: $17
Current: $5.99
Upside: +183.81%
Krystal Biotech
Jul 1, 2025
Initiates: Buy
Price Target: $190
Current: $263.99
Upside: -28.03%
CRISPR Therapeutics AG
Jun 27, 2025
Downgrades: Hold
Price Target: $45
Current: $49.70
Upside: -9.46%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.25
Upside: +566.67%
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $1.15
Upside: +682.61%
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $31.96
Upside: +109.64%
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $50.11
Upside: +111.53%
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $2.26
Upside: +961.95%
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $4.90
Upside: +1,124.49%